JP Morgan Chase
ORMP icon

JP Morgan Chase’s Oramed Pharmaceuticals ORMP Stock Holding History

JP Morgan Chase’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.7K Buy
14,158
+7,769
+122% +$30.9K ﹤0.01% 6302
2026
Q1 		$21K Sell
6,389
-10,889
-63% -$36.9K ﹤0.01% 6523
2025
Q4 		$49.2K Buy
17,278
+17,108
+10,064% +$44.1K ﹤0.01% 6233
2025
Q3 		$449 Buy
+170
New +$376 ﹤0.01% 7059
2024
Q3 		– Sell
-6,921
Closed -$17.8K – 7601
2024
Q2 		$17.8K Sell
6,921
-4,289
-38% -$10.2K ﹤0.01% 6165
2024
Q1 		$32.7K Sell
11,210
-17,556
-61% -$49.1K ﹤0.01% 6087
2023
Q4 		$66.4K Sell
28,766
-17,250
-37% -$36.8K ﹤0.01% 5903
2023
Q3 		$120K Sell
46,016
-7,835
-15% -$24.7K ﹤0.01% 5367
2023
Q2 		$193K Sell
53,851
-120,271
-69% -$386K ﹤0.01% 5094
2023
Q1 		$379K Sell
174,122
-230,495
-57% -$732K ﹤0.01% 4665
2022
Q4 		$4.87M Buy
404,617
+120,014
+42% +$933K ﹤0.01% 2841
2022
Q3 		$1.84M Sell
284,603
-51,946
-15% -$420K ﹤0.01% 3542
2022
Q2 		$1.54M Buy
336,549
+318,801
+1,796% +$1.7M ﹤0.01% 3747
2022
Q1 		$153K Sell
17,748
-17,209
-49% -$176K ﹤0.01% 5317
2021
Q4 		$499K Buy
34,957
+23,749
+212% +$497K ﹤0.01% 4824
2021
Q3 		$246K Buy
11,208
+952
+9% +$16.2K ﹤0.01% 5125
2021
Q2 		$137K Buy
+10,256
New +$117K ﹤0.01% 5426
2020
Q3 		– Sell
-13
Closed – – 5682
2020
Q2 		$0 Sell
13
-2,987
-100% -$10K ﹤0.01% 5604
2020
Q1 		$9K Buy
+3,000
New +$13.1K ﹤0.01% 5062
2018
Q1 		– Sell
-1,700
Closed -$15K – 5558
2017
Q4 		$15K Buy
1,700
+815
+92% +$7.79K ﹤0.01% 5205
2017
Q3 		$9K Buy
+885
New +$7.63K ﹤0.01% 4733
2016
Q3 		– Sell
-10
Closed – – 4725
2016
Q2 		$0 Buy
+10
New +$85 ﹤0.01% 4907

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's ORMP Position: Q2 2026 in Review

JP Morgan Chase increased its Oramed Pharmaceuticals (ORMP) stake by 122% in Q2 2026, buying an estimated $30.9K and bringing the position to 14,158 shares worth $65.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6302.

JP Morgan Chase first reported a position in ORMP in Q2 2016 and has held it in 22 quarters since. The position peaked at $4.87M in Q4 2022. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • JP Morgan Chase held 14,158 shares of Oramed Pharmaceuticals worth $65.7K as of Q2 2026.
  • JP Morgan Chase bought 7,769 Oramed Pharmaceuticals shares in Q2 2026, an estimated $30.9K.
  • Oramed Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6302 holding.
  • JP Morgan Chase first reported a position in Oramed Pharmaceuticals in Q2 2016 and has held it in 22 quarters since.
  • JP Morgan Chase's Oramed Pharmaceuticals position peaked at $4.87M in Q4 2022.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.